Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.51 |
| ▸ | ITGAV | P06756 | 8/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.51 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.51 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 3/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242674 | 0.94 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6776866 | 0.89 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6779116 | 0.89 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6777933 | 0.88 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6778587 | 0.88 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL3835297 | 0.88 | GPR139 (0.44) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6777786 | 0.87 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6779560 | 0.87 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6772198 | 0.86 | GPR139 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL6773766 | 0.86 | F7 (0.48) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.